CHEK1 (Ab-317) Antibody

What is CHEK1 (Ab-317) Antibody and what epitope does it recognize?

CHEK1 (Ab-317) Antibody is a rabbit polyclonal antibody that specifically recognizes the peptide sequence around amino acids 315-319 (S-S-S-Q-P) derived from human Chk1 protein . This antibody has been raised in rabbits through immunization with a synthetic peptide conjugated to KLH (Keyhole Limpet Hemocyanin) and subsequently purified by affinity chromatography using the epitope-specific peptide . The antibody detects endogenous levels of total Chk1 protein and has demonstrated reactivity with human and rat samples . Unlike antibodies targeting phosphorylated forms of Chk1, this antibody recognizes the total Chk1 protein regardless of its phosphorylation status.

What are the validated applications for CHEK1 (Ab-317) Antibody?

CHEK1 (Ab-317) Antibody has been validated for multiple experimental applications:

The antibody has been rigorously tested through ELISA to prove sensitivity and discriminating capacity on natural proteins, while Western blot testing has verified its specificity . For optimal results in each application, researchers should perform titration experiments to determine the ideal concentration for their specific experimental conditions.

How should CHEK1 (Ab-317) Antibody be stored to maintain optimal activity?

For optimal preservation of antibody activity, CHEK1 (Ab-317) Antibody should be stored at -20°C or -80°C upon receipt . Repeated freeze-thaw cycles should be avoided as they can lead to denaturation and decreased antibody performance . The antibody is typically supplied at a concentration of 1.0mg/mL in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, containing 150mM NaCl, 0.02% sodium azide, and 50% glycerol . The high glycerol content helps maintain stability during freeze-thaw cycles if they cannot be avoided. For short-term use (within one week), the antibody can be stored at 4°C, but should be returned to -20°C or -80°C for long-term storage.

How can I optimize Western blot protocols for CHEK1 (Ab-317) Antibody?

Optimizing Western blot protocols for CHEK1 (Ab-317) Antibody requires careful attention to several key parameters:

• Sample Preparation:

  • Extract proteins from cells using RIPA buffer supplemented with protease inhibitors

  • Include phosphatase inhibitors if studying phosphorylated forms of Chk1

  • Quantify protein concentration and load 20-50μg total protein per lane

• Gel Electrophoresis and Transfer:

  • Use 10% SDS-PAGE gels for optimal resolution of Chk1 (approximately 54 kDa)

  • Transfer to PVDF membrane at 100V for 90 minutes or 30V overnight at 4°C

• Blocking and Antibody Incubation:

  • Block membrane with 5% non-fat dry milk in TBST for 1 hour at room temperature

  • Dilute CHEK1 (Ab-317) Antibody at 1:500-1:1000 in 5% BSA in TBST

  • Incubate with primary antibody overnight at 4°C with gentle rocking

  • Wash 3-5 times with TBST (5 minutes each)

  • Incubate with HRP-conjugated secondary anti-rabbit antibody (1:5000) for 1 hour

  • Extensive washing (5-6 times) is crucial for reducing background

This protocol has been successfully used to detect endogenous Chk1 in multiple cell lines including MDA231, HeLa, and 293 cells . The antibody should produce a specific band at approximately 54 kDa corresponding to Chk1 protein.

What controls should be included when using CHEK1 (Ab-317) Antibody in immunohistochemistry?

When performing immunohistochemistry with CHEK1 (Ab-317) Antibody, the following controls are essential for result validation:

• Positive Control: Include human breast carcinoma tissue sections, which have been validated to express detectable levels of Chk1 .

• Negative Controls:

  • Omission of primary antibody (incubation with antibody diluent only)

  • Blocking peptide competition: Pre-incubate the CHEK1 (Ab-317) Antibody with its specific blocking peptide before application to tissue sections . This should eliminate specific staining, as demonstrated in the validation images for this antibody.

• Technical Controls:

  • Isotype control: Use normal rabbit IgG at the same concentration as the primary antibody

  • Tissue-negative control: Include tissue known to express minimal Chk1

• Biological Validation:

  • Parallel staining with another validated anti-Chk1 antibody targeting a different epitope

  • Correlation with Chk1 mRNA expression data if available

Immunohistochemistry results should be analyzed for both staining pattern (nuclear predominance is expected for Chk1) and intensity. The antibody has been demonstrated to effectively detect Chk1 in paraffin-embedded human breast carcinoma tissue with specific staining that can be blocked by the immunizing peptide .

How can I differentiate between total Chk1 and phosphorylated Chk1 in my experiments?

Differentiating between total Chk1 and its phosphorylated forms requires strategic experimental design:

• Antibody Selection:

  • Use CHEK1 (Ab-317) Antibody to detect total Chk1 protein regardless of phosphorylation status

  • For phosphorylated forms, use specific antibodies targeting pChk1-S317 or pChk1-S345

  • Running parallel blots or sequential probing of the same membrane allows comparison

• Treatment Conditions:

  • Include experimental conditions that modify Chk1 phosphorylation status:

    • DNA damage inducers (e.g., etoposide) increase S345 phosphorylation

    • ATR inhibitors (e.g., caffeine) prevent Chk1 phosphorylation

    • Phosphatase treatment of sample aliquots can confirm phosphorylation-specific signals

• Detection Strategy:

  • For Western blotting, phosphorylated Chk1 often appears as a slightly higher molecular weight band

  • For immunofluorescence, compare the subcellular localization patterns, as pChk1-S345 shows enhanced nuclear retention after DNA damage

• Quantitative Analysis:

  • Calculate the ratio of phosphorylated to total Chk1 as a measure of pathway activation

  • Sample data from published research shows that lysosome inhibition causes accumulation of S345 pChk1 without affecting S317 pChk1 levels

This differentiation is critical since phosphorylation at specific sites affects Chk1's degradation pathway, with S317 phosphorylation associated with proteasomal degradation and S345 phosphorylation linked to lysosomal degradation .

How is CHEK1 (Ab-317) Antibody used to study the relationship between Chk1 phosphorylation and degradation pathways?

CHEK1 (Ab-317) Antibody can be strategically employed alongside phospho-specific antibodies to elucidate the complex relationship between Chk1 phosphorylation and its degradation pathways:

• Experimental Design for Pathway Analysis:

  • Treat cells with pathway-specific inhibitors:

    • Proteasome inhibitors (MG132, bortezomib)

    • Lysosome inhibitors (chloroquine, bafilomycin A1)

    • Kinase inhibitors (ATR inhibitors like caffeine, ATM inhibitors)

  • Monitor total Chk1 levels using CHEK1 (Ab-317) Antibody

  • Simultaneously track phosphorylated forms with phospho-specific antibodies

• Key Findings from Published Research:

  • Lysosome inhibition primarily causes accumulation of S345-phosphorylated Chk1

  • S317-phosphorylated Chk1 appears to be preferentially degraded by the proteasome pathway

  • ATR kinase inhibition eliminates the Chk1 protein fraction susceptible to lysosomal degradation

• Methodology for Distinguishing Degradation Pathways:

  • Subcellular fractionation to isolate nuclear and cytoplasmic compartments

  • Co-immunoprecipitation to detect interaction with pathway-specific components:

    • hsc70 interaction indicates chaperone-mediated autophagy (CMA) targeting

    • Ubiquitinated Chk1 suggests proteasomal targeting

  • Immunofluorescence co-localization studies with lysosomal or proteasomal markers

Research has demonstrated that different phosphorylated forms of Chk1 are degraded through distinct pathways, with pChk1-S345 predominantly degraded through chaperone-mediated autophagy in lysosomes, while pChk1-S317 is primarily degraded by the proteasome . This differential regulation has important implications for Chk1's function in coordinating DNA damage response and cell cycle checkpoints.

What are the key considerations when using CHEK1 (Ab-317) Antibody to study Chk1 nuclear export mechanisms?

Studying Chk1 nuclear export mechanisms using CHEK1 (Ab-317) Antibody requires attention to several critical factors:

• Subcellular Fractionation Protocol:

  • Optimize nuclear and cytoplasmic extraction protocols to minimize cross-contamination

  • Include markers for each fraction (e.g., GAPDH for cytoplasm, histone H3 for nucleus)

  • Quantify the relative distribution of Chk1 between fractions under different conditions

• Targeting the hsc70 Interaction for Export Studies:

  • The putative hsc70 binding site (⁣³³⁶DKLVQ³⁴⁰) in Chk1 is critical for nuclear export

  • Mutation of residues 339VQ340 to alanine (Chk1-AA) disrupts hsc70 binding

  • Compare wild-type Chk1 with Chk1-AA mutant to assess export dependency on hsc70

• Experimental Conditions to Modulate Nuclear Export:

  • DNA damage induction with etoposide increases nuclear retention of Chk1

  • Cell fractionation followed by immunoblotting can quantitatively assess nuclear retention

  • Immunofluorescence with CHEK1 (Ab-317) Antibody provides spatial information on Chk1 localization

• Data Analysis and Interpretation:

  • Higher nuclear-to-cytoplasmic ratio of Chk1 indicates impaired nuclear export

  • Published research shows that L2A(-) cells (deficient in chaperone-mediated autophagy) retain more Chk1 in the nucleus after etoposide treatment

  • Cells expressing Chk1-AA mutant show higher levels of Chk1 in both cytosolic and nuclear fractions after etoposide treatment, supporting the role of hsc70 interaction in Chk1 nuclear export

Understanding Chk1 nuclear export mechanisms is important because nuclear retention of Chk1 after DNA damage enhances checkpoint function, while eventual export and degradation helps in checkpoint recovery. The interaction with hsc70 appears to be a critical determinant of Chk1 nuclear export and subsequent lysosomal degradation under conditions of DNA damage .

How can CHEK1 (Ab-317) Antibody be used in combination with other antibodies to study the ATR-Chk1 signaling pathway?

Combining CHEK1 (Ab-317) Antibody with other pathway-specific antibodies enables comprehensive analysis of the ATR-Chk1 signaling cascade:

• Antibody Panel for ATR-Chk1 Pathway Analysis:

  • CHEK1 (Ab-317): Total Chk1 levels

  • Phospho-Chk1 (S345): ATR-mediated activation

  • Phospho-Chk1 (S317): ATR-mediated activation

  • ATR antibody: Upstream kinase levels

  • Phospho-ATR: Activated upstream kinase

  • γH2AX: DNA damage marker

  • Downstream effectors: CDC25A, WEE1, p53

• Experimental Design for Pathway Activation and Inhibition:

  • Activation: Treat cells with replication stress inducers (hydroxyurea, aphidicolin) or DNA damaging agents (UV, etoposide)

  • Inhibition: Use specific ATR inhibitors (caffeine, VE-821, AZD6738) or Chk1 inhibitors

  • Time-course experiments to capture signaling dynamics

• Multiplexed Detection Methods:

  • Sequential immunoblotting of the same membrane

  • Multiplex immunofluorescence with different fluorophore-conjugated secondary antibodies

  • Flow cytometry for single-cell analysis of pathway activation

• Quantitative Analysis of Pathway Activation:

  • Measure phospho-Chk1/total Chk1 ratio under different conditions

  • Correlate ATR activation with Chk1 phosphorylation and downstream effects

  • Example data from research shows that inhibition of ATR markedly reduces the fraction of pChk1 degraded in lysosomes, while after etoposide treatment, only caffeine (an ATR inhibitor) was capable of inhibiting pChk1 lysosomal degradation

This combinatorial approach allows researchers to:

• Determine the activation state of the pathway

• Identify rate-limiting steps in signal transduction

• Assess the effects of targeting specific pathway components

• Understand pathway cross-talk with other cellular processes

What are common issues when using CHEK1 (Ab-317) Antibody and how can they be resolved?

Researchers working with CHEK1 (Ab-317) Antibody may encounter several challenges that can be systematically addressed:

• High Background in Western Blots:

  • Causes: Insufficient blocking, antibody concentration too high, inadequate washing

  • Solutions:

    • Increase blocking time (2 hours or overnight)

    • Optimize antibody dilution (try 1:1000 instead of 1:500)

    • Extend washing steps (5 x 10 minutes with TBST)

    • Use 5% BSA instead of milk for diluting antibody

• Weak or No Signal:

  • Causes: Low Chk1 expression, protein degradation, inefficient transfer

  • Solutions:

    • Include positive control (e.g., MDA231, HeLa, or 293 cell lysates)

    • Add protease inhibitors to lysis buffer

    • Verify transfer efficiency with Ponceau S staining

    • Reduce washing stringency or increase antibody concentration

    • Extend exposure time for detection

• Multiple Bands in Western Blot:

  • Causes: Protein degradation, cross-reactivity, post-translational modifications

  • Solutions:

    • Validate with blocking peptide competition

    • Include phosphatase treatment to distinguish phosphorylated forms

    • Use freshly prepared lysates with protease inhibitors

    • Compare band patterns with published literature

• Variable Staining in Immunohistochemistry:

  • Causes: Tissue fixation differences, antigen retrieval issues

  • Solutions:

    • Optimize antigen retrieval method (citrate vs. EDTA buffer)

    • Standardize fixation protocols

    • Titrate antibody concentration for each tissue type

    • Include validated positive control tissues

• Inconsistent Results Between Experiments:

  • Causes: Antibody stability issues, protocol variations

  • Solutions:

    • Aliquot antibody to avoid repeated freeze-thaw cycles

    • Standardize protocols with detailed SOPs

    • Use the same lot number of antibody when possible

    • Maintain consistent experimental conditions

For all troubleshooting scenarios, comparing results with published data using this antibody can provide valuable reference points for expected outcomes and signal patterns.

How should researchers interpret changes in Chk1 localization and phosphorylation in response to DNA damage?

Interpreting changes in Chk1 localization and phosphorylation requires understanding the normal dynamics of this protein during DNA damage response:

• Normal Chk1 Dynamics During DNA Damage:

  • Baseline: Predominantly diffuse nuclear and cytoplasmic distribution

  • Early after damage: Increased phosphorylation at S345 and S317 by ATR

  • Mid-response: Nuclear accumulation of phosphorylated Chk1

  • Late response: Nuclear export and degradation during recovery

• Interpreting Localization Changes:

  • Nuclear retention of Chk1 after DNA damage indicates active checkpoint signaling

  • Immunoblot analysis of nuclear fractions shows higher retention of Chk1 in L2A(-) cells treated with etoposide

  • Immunofluorescence data confirms increased nuclear Chk1 in these conditions

  • Cytoplasmic translocation during recovery phase suggests checkpoint termination

• Phosphorylation Pattern Analysis:

  • S345 phosphorylation: Primary indicator of ATR-mediated activation

  • S317 phosphorylation: Also ATR-dependent but with distinct degradation fate

  • Lysosome inhibition causes accumulation primarily of S345 pChk1

  • S317 pChk1 appears to be the preferred substrate for proteasome-dependent degradation

• Correlation With Cellular Outcomes:

  • Sustained nuclear pChk1 correlates with prolonged cell cycle arrest

  • Failed nuclear export may indicate defective checkpoint recovery

  • Abnormal degradation patterns suggest dysregulated checkpoint control

  • The interaction between Chk1 and hsc70 appears critical for nuclear export, as mutation of the hsc70 binding site results in higher stability and nuclear retention of Chk1

When interpreting experimental results, researchers should consider the timing of their analysis relative to DNA damage induction, as Chk1 dynamics are highly temporal. Combining multiple detection methods (Western blot, immunofluorescence, fractionation) provides the most comprehensive view of Chk1 regulation during the DNA damage response.

How can conflicting results between different detection methods for Chk1 be reconciled when using CHEK1 (Ab-317) Antibody?

When faced with conflicting results between different detection methods using CHEK1 (Ab-317) Antibody, researchers should follow a systematic approach to reconciliation:

How might CHEK1 (Ab-317) Antibody be used in studying Chk1 as a therapeutic target in cancer?

CHEK1 (Ab-317) Antibody offers valuable applications for studying Chk1 as a therapeutic target in cancer research:

• Target Validation Studies:

  • Assess baseline Chk1 expression across cancer types using tissue microarrays

  • Correlate Chk1 levels with response to DNA-damaging therapies

  • Identify cancer subtypes with Chk1 dependency through expression profiling

  • Example application: Immunohistochemical analysis of human breast carcinoma tissue samples has already demonstrated the utility of this antibody for cancer tissue analysis

• Pharmacodynamic Biomarker Development:

  • Monitor total Chk1 levels in response to Chk1 inhibitors

  • Track changes in subcellular localization during treatment

  • Develop assays to measure drug-target engagement in clinical samples

  • Multiplexed analysis with phospho-specific antibodies to monitor pathway inhibition

• Resistance Mechanism Exploration:

  • Investigate alterations in Chk1 degradation pathways in resistant models

  • Examine changes in Chk1 nuclear export in treatment-resistant cells

  • Study compensatory signaling when Chk1 is inhibited

  • Correlate Chk1 status with clinical outcomes and treatment response

• Combination Therapy Rationale:

  • Assess Chk1 activation in response to various DNA-damaging agents

  • Evaluate synergistic effects of Chk1 inhibitors with standard therapies

  • Monitor changes in Chk1 degradation mechanisms with different drug combinations

  • Develop predictive biomarkers for patient stratification

• Methodological Approach:

  • Use CHEK1 (Ab-317) Antibody in conjunction with phospho-specific antibodies to assess pathway activation

  • Employ immunohistochemistry on patient-derived xenografts treated with Chk1 inhibitors

  • Develop quantitative imaging protocols for digital pathology analysis

  • Implement multiplexed detection systems for simultaneous analysis of multiple biomarkers

Research suggests that distinct degradation pathways for different phosphorylated forms of Chk1 could provide novel therapeutic opportunities . Understanding how cancer cells regulate Chk1 through these pathways may reveal new approaches to enhance the efficacy of Chk1-targeted therapies or overcome resistance mechanisms.

What emerging techniques could enhance the utility of CHEK1 (Ab-317) Antibody in research?

Several emerging techniques could significantly enhance the research applications of CHEK1 (Ab-317) Antibody:

• Proximity Ligation Assays (PLA):

  • Enables detection of protein-protein interactions in situ

  • Application: Visualize interactions between Chk1 and hsc70 or other pathway components

  • Advantages: Single-molecule sensitivity, spatial resolution, quantifiable signal

  • Implementation: Combine CHEK1 (Ab-317) Antibody with antibodies against potential interaction partners

• Mass Cytometry (CyTOF):

  • Allows simultaneous detection of >40 parameters at single-cell level

  • Application: Multi-parameter analysis of Chk1 pathway in heterogeneous samples

  • Advantages: No spectral overlap issues, high-dimensional data

  • Implementation: Metal-conjugated CHEK1 (Ab-317) Antibody combined with other pathway markers

• Spatial Transcriptomics with Protein Detection:

  • Correlates protein expression with transcriptional states in tissue context

  • Application: Link Chk1 protein levels to gene expression programs in tumors

  • Advantages: Provides mechanistic insights into Chk1 regulation

  • Implementation: Combine immunofluorescence using CHEK1 (Ab-317) Antibody with in situ RNA sequencing

• Live-Cell Imaging with Nanobody Derivatives:

  • Generate nanobody versions of anti-Chk1 antibodies for live imaging

  • Application: Real-time tracking of Chk1 dynamics during DNA damage response

  • Advantages: Temporal resolution, non-invasive monitoring

  • Implementation: Engineer fluorescently tagged nanobodies based on CHEK1 (Ab-317) Antibody epitope specificity

• Super-Resolution Microscopy:

  • Achieves resolution below diffraction limit (~20-50nm)

  • Application: Detailed visualization of Chk1 subcellular localization

  • Advantages: Reveals previously undetectable spatial patterns

  • Implementation: Optimize CHEK1 (Ab-317) Antibody staining protocols for STORM, PALM, or STED microscopy

• Microfluidic Antibody Capture and Analysis:

  • Enables analysis from limited sample volumes

  • Application: Monitor Chk1 status from circulating tumor cells or fine-needle aspirates

  • Advantages: Clinical translation potential, minimal sample requirements

  • Implementation: Immobilize CHEK1 (Ab-317) Antibody in microfluidic channels for capture and analysis

These emerging techniques would address current limitations in studying Chk1 biology, particularly regarding temporal dynamics, protein interactions, and single-cell heterogeneity, potentially revealing new aspects of Chk1 function in normal and disease states.

How can CHEK1 (Ab-317) Antibody contribute to understanding the non-canonical functions of Chk1?

CHEK1 (Ab-317) Antibody can be strategically employed to investigate the emerging non-canonical functions of Chk1 beyond its established role in DNA damage response:

• Chk1 in Gene Transcription Regulation:

  • Experimental Approach:

    • Chromatin immunoprecipitation (ChIP) using CHEK1 (Ab-317) Antibody

    • Correlation of nuclear Chk1 levels with transcriptional profiles

    • Analysis of Chk1 association with transcription factors

  • Methodological Considerations:

    • Optimize crosslinking conditions for nuclear proteins

    • Include appropriate controls for antibody specificity in ChIP

    • Compare results under normal and DNA damage conditions

• Chk1 in Embryonic Development:

  • Experimental Approach:

    • Immunohistochemistry of developmental tissue sections

    • Temporal analysis of Chk1 expression during differentiation

    • Correlation with developmental markers

  • Technical Implementation:

    • Validate antibody reactivity in developmental tissue samples

    • Optimize antigen retrieval for embryonic tissues

    • Implement multiplexed detection with developmental markers

• Chk1 in Cytoplasmic Signaling Networks:

  • Experimental Approach:

    • Immunoprecipitation with CHEK1 (Ab-317) Antibody followed by mass spectrometry

    • Subcellular fractionation to isolate cytoplasmic Chk1 complexes

    • Co-localization studies with cytoplasmic organelle markers

  • Analytical Strategy:

    • Compare Chk1 interaction partners in different cellular compartments

    • Analyze interactions in the presence of various stressors

    • Validate interactions through reciprocal co-immunoprecipitation

• Chk1 in Cell Viability Regulation:

  • Experimental Approach:

    • Correlate Chk1 levels and localization with markers of cell death pathways

    • Monitor Chk1 dynamics during various cell death modes

    • Assess relationship between Chk1 degradation pathways and cell survival

  • Research Design:

    • Time-course experiments following induction of different cell death pathways

    • Genetic manipulation of Chk1 degradation pathways

    • Comparative analysis across cell types with varying dependency on Chk1

Research has already established connections between Chk1 and cellular functions beyond canonical DNA damage response, including gene transcription, embryo development, and somatic cell viability . The CHEK1 (Ab-317) Antibody, which detects total Chk1 regardless of phosphorylation status, is particularly valuable for studying these non-canonical functions that may not depend on the classical ATR-mediated phosphorylation events.

Understanding these non-canonical functions may provide insights into unexplained phenotypes associated with Chk1 manipulation and potential off-target effects of Chk1 inhibitors in clinical development.